**Core Concept:**
Urothelial carcinoma is a type of cancer that originates from the urothelial cells lining the urinary tract. Clear cell variant occurs commonly in renal cell carcinoma but can also be seen in other organs like the bladder, ureter, and kidney.

**Why the Correct Answer is Right:**
The correct answer is D (FGFR3 mutation). Clear cell variant of urothelial carcinoma often has specific genetic mutations, one of which is a mutation in the Fibroblast Growth Factor Receptor 3 (FGFR3) gene. This mutation leads to the production of a non-functional protein, resulting in increased cell proliferation and the characteristic clear cytoplasm.

**Why Each Wrong Option is Incorrect:**
A (TP53 mutation) and B (KRAS mutation) are other gene mutations associated with urothelial carcinoma, but not specifically with the clear cell variant. C (VHL mutation) is associated with von Hippel-Lindau disease, a different condition involving hemangioblastomas, renal cysts, and papillary renal cell carcinoma, not clear cell variant of urothelial carcinoma.

**Clinical Pearl:**
The correct answer (FGFR3 mutation) is crucial as it helps in understanding the molecular basis of clear cell variant of urothelial carcinoma and the importance of genetic testing in determining the appropriate treatment and prognosis for patients with this type of cancer.

**Correct Answer:** FGFR3 mutation

**Why the Correct Answer is Right:**
The correct answer, Fibroblast Growth Factor Receptor 3 (FGFR3) mutation, is relevant in understanding the pathogenesis of clear cell variant of urothelial carcinoma. This mutation leads to the production of a non-functional protein, resulting in increased cell proliferation and the characteristic clear cytoplasm of the tumor cells. Identifying this mutation can be helpful in determining the appropriate treatment and prognosis for patients with clear cell variant of urothelial carcinoma.

**Why Each Wrong Option is Incorrect:**
A (TP53 mutation) is involved in other types of urothelial carcinoma, but not specifically the clear cell variant. B (KRAS mutation) is more commonly associated with colorectal cancer and other types of solid tumors, not urothelial carcinoma. C (VHL mutation) is related to von Hippel-Lindau disease, a different condition involving renal cysts, hemangioblastomas, and papillary renal cell carcinoma, not clear cell variant of urothelial carcinoma.